BioSpace News Archive

Vivera Pharmaceuticals today announced the introduction of Vivera BioSciences, a new division of the Company focused exclusively on research and innovation in drug delivery.

Ubiquigent Limited today announces the extension and expansion of its long-term collaboration with Bristol Myers Squibb.

Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), announced today that management will provide a corporate update at the Stifel 2021 Virtual Healthcare Conference, which is being held November 15-17, 2021.

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Swissmedic has authorized a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 µg dose level in particularly vulnerable individuals 12 years of age and older, at least six months after completion of the primary series.

Centinel Spine®, LLC, today announced the recent publication of a research study on its STALIF C-Ti® product in the Journal of Surgery & Anesthesia Research: “Preliminary 12-Month Safety and Efficacy Outcomes for the Treatment of Cervical Radiculopathy and Myelopathy with the Stalif-C Integrated Interbody Fusion Device.”

The International Society of Gastrointestinal Oncology, a nonprofit global educational organization committed to gastrointestinal oncology, recently named Dr. Weijing Sun its new president.

Moderna, Inc. (Nasdaq: MRNA), today announced the first participant has been dosed in the Phase 3 pivotal registration study of mRNA-1647, the Company’s cytomegalovirus (CMV) vaccine candidate.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the Company will present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 in adults with relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit.